<DOC>
	<DOCNO>NCT01721135</DOCNO>
	<brief_summary>This study randomize , placebo control , four way crossover , effect GSK2190915 QTc interval assess . Healthy subject recieve 5 day course follow ; oral placebo , GSK2190915 100mg , GSK2190915 1000mg moxifloxacin 400mg ( single dose ) week washout prior start next course . Key assessment include 12- lead electrocardiogram pharmacokinetic testing . Safety assess blood pressure , heart rate , clinical laboratory safety test collection adverse event .</brief_summary>
	<brief_title>A Study Evaluate Effect Two Different Repeat Doses GSK2190915 QTc Interval .</brief_title>
	<detailed_description>This randomize , placebo control , four way crossover thorough QT study evaluate effect repeat dose GSK2190915 QTc interval healthy male female subject . Approximately 48 subject receive oral placebo , GSK2190915 ( 100mg 1000mg ) moxifloxacin ( 400mg ) . GSK2190915 match placebo give daily 5 day moxifloxacin match placebo give Day 5 . Moxifloxacin ( positive control ) give single-blind single dose Day 5 placebo administer Days 1-4 . Individual time-matched change baseline QTcF ( difference placebo ) GSK2190915 determine 0-24 hour dose Day 5 ( primary endpoint ) . Secondary endpoint include change baseline QTcF , QTcB QT interval timepoint 5 day dose GSK2190915 single dose moxifloxacin ( 400mg ) . Plasma concentration Day 5 ( 0-24 hour ) pharmacokinetic parameter GSK2190915 also derive .</detailed_description>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Male female 18 65 year age inclusive Aspartate aminotransferase ( AST ) , Alanine aminotransferase ( ALT ) , alkaline phosphatase bilirubin â‰¤ 1.5x Upper limit normal ( ULN ) Healthy determine physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method . Those childbearing potential must agree use one protocol contraception method . Body mass index ( BMI ) within range 18.529.0 kg/m2 ( inclusive ) Capable give write informed consent Current nonsmoker use tobacco product 6 month period precede screen No significant abnormality 12lead electrocardiogram ( ECG ) screen A 24 hour Holter ECG screen demonstrates clinically significant abnormality A physician deems subject unsuitable study A screening Holter ECG trace reveals clinically concern arrhythmias A blood pressure persistently high 140/90 millimetre mercury ( mmHg ) screening . A mean heart rate outside range 4090 beat per minute ( bpm ) screening . History presence medically significant disease , disorder . In particular , family history QT prolongation , early sudden cardiac death early cardiovascular disease . A positive result Hepatitis B Hepatitis C within 3 month screen Current chronic history liver disease , know hepatic biliary abnormality A positive prestudy drug/alcohol screen A positive test Human Immunodeficiency Virus ( HIV ) antibody History regular alcohol consumption within 6 month study The subject participate clinical trial receive investigational product within 3 month first dose day current study Exposure four new chemical entity within 12 month prior first dose day Use prescription nonprescription drug , include vitamin , herbal dietary supplement 14 day screen followup visit unless permitted investigator History sensitivity study medication Where participation study would result donation blood blood product excess 500 mL within 3 month period Pregnant females Lactating female Unwillingness inability follow procedure outline protocol Subject mentally legally incapacitate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>moxifloxacin</keyword>
	<keyword>GSK2190915</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>QTc</keyword>
</DOC>